n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
- PMID: 22686415
- DOI: 10.1056/NEJMoa1203859
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
Abstract
Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown.
Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here.
Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups.
Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Comment in
-
Diabetes: basal insulin and n-3 fatty acids--no effect on cardiovascular outcomes.Nat Rev Endocrinol. 2012 Jun 26;8(8):446. doi: 10.1038/nrendo.2012.111. Nat Rev Endocrinol. 2012. PMID: 22733269 No abstract available.
-
Diabetes: Does glycemic control reduce cardiovascular event rates?Nat Rev Cardiol. 2012 Jul 3;9(8):434. doi: 10.1038/nrcardio.2012.96. Nat Rev Cardiol. 2012. PMID: 22751264 No abstract available.
-
ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.Ann Intern Med. 2012 Sep 18;157(6):JC3-11. doi: 10.7326/0003-4819-157-6-201209180-02011. Ann Intern Med. 2012. PMID: 22986403 No abstract available.
-
n-3 fatty acids and cardiovascular outcomes in dysglycemia.N Engl J Med. 2012 Nov 1;367(18):1760; author reply 1761. doi: 10.1056/NEJMc1210552. N Engl J Med. 2012. PMID: 23113491 No abstract available.
-
n-3 fatty acids and cardiovascular outcomes in dysglycemia.N Engl J Med. 2012 Nov 1;367(18):1760-1; author reply 1761. doi: 10.1056/NEJMc1210552. N Engl J Med. 2012. PMID: 23113492 No abstract available.
-
N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia.Evid Based Med. 2013 Aug;18(4):e34. doi: 10.1136/eb-2012-101012. Epub 2012 Nov 21. Evid Based Med. 2013. PMID: 23173155 No abstract available.
Similar articles
-
Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686416 Clinical Trial.
-
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.Lancet Diabetes Endocrinol. 2014 Jul;2(7):562-72. doi: 10.1016/S2213-8587(14)70062-2. Epub 2014 Jun 2. Lancet Diabetes Endocrinol. 2014. PMID: 24898834 Clinical Trial.
-
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917545 Clinical Trial.
-
[What has the largest study in the history of diabetology brought us?].Vnitr Lek. 2013 Mar;59(3):160-4. Vnitr Lek. 2013. PMID: 23713181 Review. Czech.
-
Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.Postgrad Med. 2018 Mar;130(2):154-158. doi: 10.1080/00325481.2018.1430446. Epub 2018 Jan 25. Postgrad Med. 2018. PMID: 29350569 Review.
Cited by
-
Omega-3 fatty acids for intermittent claudication.Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD003833. doi: 10.1002/14651858.CD003833.pub5. Cochrane Database Syst Rev. 2024. PMID: 39470212
-
The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials.Front Nutr. 2024 Sep 30;11:1423228. doi: 10.3389/fnut.2024.1423228. eCollection 2024. Front Nutr. 2024. PMID: 39403396 Free PMC article.
-
Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis.JAMA Netw Open. 2024 Sep 3;7(9):e2432296. doi: 10.1001/jamanetworkopen.2024.32296. JAMA Netw Open. 2024. PMID: 39240561 Free PMC article.
-
Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials.Ann Med Surg (Lond). 2024 Jul 3;86(9):4941-4943. doi: 10.1097/MS9.0000000000002215. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39238993 Free PMC article. No abstract available.
-
Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes.Cardiovasc Diabetol. 2024 Sep 3;23(1):325. doi: 10.1186/s12933-024-02383-z. Cardiovasc Diabetol. 2024. PMID: 39227845 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical